MAP plus maintenance pegylated interferon α-2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization.

• Bielack, Stefan S. Klinikum Stuttgart, Olgahospital, Cooperative Osteosarcoma Study Group (COSS), Stuttgart, Germany
• Smeland, Sigbjorn Oslo University Hospital, The Norwegian Radium Hospital, Scandinavian Sarcoma Group, Oslo, Norway
• Whelan, Jeremy University College London Hospitals NHS Foundation Trust, London, United Kingdom
• Marina, Neyssa Stanford University, School of Medicine, Palo Alto, CA
• Hook, Jane MRC Clinical Trials Unit, London, United Kingdom
• Jovic, Gordana MRC Clinical Trials Unit, London, United Kingdom
• Krailo, Mark D. Children's Oncology Group, Arcadia, CA
• Butterfass-Bahloul, Trude Center for Clinical Trials, University of Muenster, Muenster, Germany
• Kühne, Thomas University Children’s Hospital Basel, Basel, Switzerland
• Eriksson, Mikael Skane University Hospital and Lund University, Lund, Sweden
• Teot, Lisa A. Children's Hospital Boston, Boston, MA
• Gelderblom, Hans Department of Clinical Oncology, Leiden University Medical Center, Leiden, Netherlands
• Kager, Leo St Anna's Children's Hospital, Vienna, Austria
• Sundby Hall, Kirsten Oslo University Hospital, The Norwegian Radium Hospital, Scandinavian Sarcoma Group, Oslo, Norway
• Gorlick, Richard Greg The Children's Hospital, Bronx, NY
• Randall, R. Lor Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
• Hogendoorn, Pancras C. W. Department of Pathology, Leiden University Medical Center, Leiden, Netherlands
• Calaminus, Gabriele University Hospital of Muenster, Muenster, Germany
• Sydes, Matthew Robert MRC Clinical Trials Unit, London, United Kingdom
• Bernstein, Mark L. IWK Health Center, Dalhousie University, Halifax, NS, Canada

Cancer Research

Oncology